- Home
- DOCS vs ASND Comparison
DOCS vs ASND Comparison
Compare DOCS & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCS | ASND |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 12.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DOCS | ASND |
|---|---|---|
| Price | $46.10 | $205.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 15 |
| Target Price | $68.05 | ★ $256.27 |
| AVG Volume (30 Days) | ★ 2.7M | 640.2K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.88 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | $621,329,000.00 | ★ $758,592,045.00 |
| Revenue This Year | $15.22 | $99.74 |
| Revenue Next Year | $11.03 | $79.40 |
| P/E Ratio | $36.78 | ★ N/A |
| Revenue Growth | 20.21 | ★ 97.46 |
| 52 Week Low | $45.29 | $118.03 |
| 52 Week High | $85.21 | $223.19 |
Technical Indicators
Market Signals| Indicator | DOCS | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 28.80 | 49.03 |
| Support Level | $50.10 | $198.30 |
| Resistance Level | $51.80 | $218.50 |
| Average True Range (ATR) | 2.18 | 9.16 |
| MACD | 0.49 | -0.64 |
| Stochastic Oscillator | 9.53 | 28.05 |
Price Performance
Historical ComparisonAbout DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.